CoChat
Sign Up
Cited by 47

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE ε4 allele

Rodríguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., Combarros, O.·2006·Journal of Neurology
DOI 10.1007/s00415-005-0945-2
Open this paper in CoChat — free account

Abstract

Cholesterol regulates the production of amyloid beta (Abeta), which is central to the pathogenesis of Alzheimer's disease (AD), with high cellular cholesterol promoting and low cellular cholesterol reducing Abeta in vitro and in vivo. High density lipoprotein (HDL) plays a central role in the removal of excess cholesterol from cells, and cholesteryl ester transfer protein (CETP) is a crucial protein involved in the regulation of HDL levels. Two common polymorphisms in the promoter region (C-629A) and exon 14 I405V of the CETP gene are associated with CETP activity and HDL levels. To investigate if these sequence variants in CETP might be of importance in mediating susceptibility to AD, independently or in concert with apolipoprotein E (APOE) epsilon4 allele, we studied a sample of 286 Spanish AD patients and 315 healthy controls. In APOE epsilon4 carriers, homozygous for the CETP (-629) A allele had approximately a three times lower risk of developing AD (odds ratio 2.33, 95% CI 1.01-5.37), than homozygous and heterozygous carriers of the CETP (-629) C allele (odds ratio 7.12, 95% CI 4.51-11.24, P for APOE epsilon4/CETP (-629) AA genotype interaction < 0.001). Our data suggest that CETP behaves as a modifier gene of the AD risk associated with the APOE epsilon4 allele, possibly through modulation of brain cholesterol metabolism.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00415-005-0945-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Albers JJ, Tollefson JH, Wolfbauer G, Albright RE Jr (1992) Cholesteryl ester transfer protein in human brain. Int J Clin Lab Res 21:264–266 · DOI
  2. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR (2003) Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290:2030–2040 · DOI
  3. Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ, Meyer J, Cambien F, Tiret L (2003) Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 41:1983–1989 · DOI
  4. Boekholdt SM, Thompson JF (2003) Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 44:1080–1093 · DOI
  5. Brewer HB (2004) Increasing HDL cholesterol levels. N Engl J Med 350:1491–1494 · DOI
  6. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M (2000) New functional promoter polymorphism, CETP (–629), in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels. Role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 20:507–515 · DOI
  7. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105–112 · DOI · Paper page
  8. Fidani L, Goulas A, Crook R, Petersen RC, Tangalos E, Kotsis A, Hardy J (2004) An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. Neurosci Lett 357:152–154 · DOI
  9. Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, Estus S (2005) Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging 26:1–7 · DOI · Paper page
  10. Lambert JC, Luedecking–Zimmer E, Merrot S, Hayes A, Thaker U, Desai P, Houzet A, Hermant X, Cottel D, Pritchard A, Iwatsubo T, Pasquier F, Frigard B, Conneally PM, Chartier– Harlin MC, DeKosky ST, Lendon C, Mann D, Kamboh MI, Amouyel P (2003) Association of 3'–UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. J Med Genet 40:424–430 · DOI
  11. Macé S, Cousin E, Ricard S, Génin E, Spanakis E, Lafargue–Soubigou C, Génin B, Fournel R, Roche S, Haussy G, Massey F, Soubigou S, Bréfort G, Benoit P, Brice A, Campion D, Hollis M, Pradier L, Benavides J, Deleuze JF (2005) ABCA2 is a strong genetic risk factor for early–onset Alzheimer's disease. Neurobiol Dis 18:119–125 · DOI
  12. McKhaan G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDA–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:934–944 · DOI
  13. Michikawa M (2003) The role of cholesterol in pathogenesis of Alzheimer's disease. Dual metabolic interaction between amyloid β–protein and cholesterol. Mol Neurobiol 27:1–12 · DOI
  14. Olesen OF, Dago (2000) High density lipoprotein inhibits assembly of amyloid β–peptides into fibrils. Biochem Biophys Res Commun 270:62–66 · DOI
  15. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lütjohann D, Ghebremedhin E, Hegi T, Pasch T, Träxler M, Brühl A, Benussi L, Binetti G, Braak H, Nitsch RM, Hock C (2003) Increased brain β–amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60:29–35 · DOI
  16. Poirier J (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9:94–101 · DOI · Paper page
  17. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6: 345–351 · DOI · Paper page
  18. Sánchez–Guerra M, Combarros O, Infante J, Llorca J, Berciano J, Fontalba A, Fernández–Luna JL, Peña N, Fernández– Viadero C (2001) Case–control study and meta–analysis of low density lipoprotein receptor–related protein gene exon 3 polymorphism in Alzheimer's disease. Neurosci Lett 316:17–20 · DOI
  19. Thompson JF, Lira ME, Durham K, Clark RW, Bamberger MJ, Milos PM (2003) Polymorphisms in the CETP gene and association with CETP mass and HDL levels. Atherosclerosis 167:195–204 · DOI
  20. Thompson JF, Lloyd DB, Lira ME, Milos PM (2004) Cholesteryl ester transfer protein promoter singlenucleotide polymorphisms in Sp1– binding sites affect transcription and are associated with high–density lipoprotein cholesterol. Clin Genet 66:223–228 · DOI
  21. van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJP (2004) Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol 15:631–636 · DOI
  22. Wolozin B (2004) Cholesterol, statins and dementia. Curr Opin Lipidol 15:667–672 · DOI
  23. Wollmer MA, Streffer JR, Lütjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, von Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24:421–426 · DOI
  24. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LME, Lütjohann D, Thal D, von Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) Genetic association of acyl–coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol Psychiatry 8:635–638 · DOI
  25. Yamada T, Kawata M, Arai H, Fukusawa M, Inoue K, Sato T (1995) Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Acta Neuropathol (Berl) 90:633–636 · DOI
  26. Yanagisawa K (2002) Cholesterol and pathological processes in Alzheimer's disease. J Neurosci Res 70:361–366 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rodríguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., & Combarros, O.
Venue
Journal of Neurology
Publisher
Springer Science and Business Media LLC
Published
2005-08-17
Volume
253
Issue
2
Pages
181-185
ISSN
  • 0340-5354
  • 1432-1459
DOI
10.1007/s00415-005-0945-2
Cited by
47
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review